The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of BRAF class I/II/III mutations, demographics, and treatment outcomes in NSCLC.
 
Julian Andres Marin-Acevedo
No Relationships to Disclose
 
James Kevin Hicks
Consulting or Advisory Role - 23andMe; Quest Diagnostics
Research Funding - OneOme
 
Ram Thapa
No Relationships to Disclose
 
Dung-Tsa Chen
No Relationships to Disclose
 
ErinMarie Kimbrough
No Relationships to Disclose
 
Jhanelle Elaine Gray
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Axiom Healthcare Strategies; Axiom Healthcare Strategies; Blueprint Medicines; Bristol Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; EMD Serono; EMD Serono; Inivata; Janssen Scientific Affairs; Lilly; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Sanofi
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Inivata; Merck; Merck Sharp & Dohme; Novartis